Want to see AKTS full AI Analyst Report?

Aktis Oncology, Inc. (AKTS) Price & Analysis

42 Followers

AKTS Stock Chart & Stats

$26.92

Market closed

$26.92

Day’s Range― - ―

52-Week Range$14.72 - $34.19

Previous CloseN/A

VolumeN/A

Average Volume (3M)438.66K

Market Cap

$890.47M

Enterprise Value$1.28B

Total Cash (Recent Filing)$517.32M

Total Debt (Recent Filing)$11.24M

Price to Earnings (P/E)―

Beta2.45

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding53,746,670

10 Day Avg. Volume360,071

30 Day Avg. Volume438,663

Financial Highlights & Ratios

PEG Ratio3.39

Price to Book (P/B)-8.05

Price to Sales (P/S)181.08

P/FCF Ratio-15.96

Enterprise Value/Market Cap1.43

Enterprise Value/Revenue126.92

Enterprise Value/Gross Profit149.71

Enterprise Value/Ebitda-16.42

Forecast

1Y Price Target

$35.80

Price Target Upside32.99% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue ExpansionRevenue grew about 596% in 2025, showing that the company is converting its development and commercial activities into a materially larger top line. If this expansion persists, a broader revenue base could improve operating leverage and provide more resources for advancing its oncology pipeline over the next several quarters.

Gross MarginA strong reported gross margin indicates that revenue may carry meaningful contribution potential before operating expenses. Although profitability remains distant, preserving this margin profile as revenue scales could support future operating leverage and improve the economics of successful oncology products.

Oncology Pipeline FocusAktis is focused on novel cancer therapeutics, giving its research effort a clear disease-area specialization rather than a broadly dispersed strategy. Concentrated oncology development can build domain expertise and create multiple opportunities for pipeline progress over the medium term.

Bears Say

Severe LossesThe scale of the 2025 net loss relative to revenue shows that the company remains far from self-sustaining profitability. Large operating losses can consume capital needed for research and development, making successful execution and eventual revenue growth critical to financial durability.

Negative EquityDeepening negative equity signals that accumulated losses have materially weakened the capital structure. This reduces financial flexibility and can increase dependence on new financing, while any funding raised under pressure may create dilution that limits the value retained by existing shareholders.

Cash BurnThe return to substantial operating and free cash flow burn indicates elevated funding needs while the company continues investing in its business. Persistent cash consumption can constrain strategic flexibility and leave progress dependent on access to external capital over coming quarters.

Aktis Oncology, Inc. News

Aktis Oncology initiates second Phase 1b trial for AKY-2519

Aktis Oncology (AKTS) announced the initiation of the Phase 1b BActinium-2 trial of AKY-25191 in patients with NSCLC...

16d ago

AKTS

Oppenheimer bullish on Aktis Oncology, initiates with an Outperform

As previously reported, Oppenheimer initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $40 price target...

1M ago

AKTS

Aktis Oncology initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $40 price target Published first on...

1M ago

AKTS

Wedbush starts Aktis Oncology at Outperform on radiopharma potential

Wedbush analyst David Nierengarten initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $35 price target...

2M ago

AKTS

Aktis Oncology initiated with an Outperform at Wedbush

Wedbush analyst David Nierengarten initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $35 price target...

2M ago

AKTS

BMO starts Aktis at Outperform, says opportunities not captured in valuation

BMO Capital analyst David Lebowitz initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $37 price...

2M ago

AKTS

Aktis Oncology initiated with an Outperform at BMO Capital

BMO Capital analyst David Lebowitz initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $37 price...

2M ago

AKTS

Aktis Oncology reports Q2 revenue $3.38M, consensus $2.58M

“This was a quarter of strong execution for Aktis, focused on generating clinical data and building infrastructure to...

2M ago

AKTS

Fifteen new option listings on July 15th

New option listings for July 15th include Aktis Oncology Inc (AKTS), Avidia Bancorp Inc (AVBC), Infoblox Inc (BLOX),...

3M ago

AKTS

AVBC

Aktis Oncology Initiated at Buy on AKY-1189’s Potential to Surpass Current Second-Line Bladder Cancer Chemotherapy Benchmark

William Blair analyst Alexandra Ramsey has maintained their bullish stance on AKTS stock, giving a Buy rating today....

3M ago

AKTS

Aktis Oncology price target raised to $33 from $30 at JPMorgan

JPMorgan raised the firm’s price target on Aktis Oncology (AKTS) to $33 from $30 and keeps an Overweight...

3M ago

AKTS

Early Clinical Data and Differentiated Miniprotein Platform Underpin Buy Rating on Aktis for B7-H3 Radiopharmaceutical in mCRPC

William Blair analyst Alexandra Ramsey has reiterated their bullish stance on AKTS stock, giving a Buy rating yesterday....

5M ago

AKTS

Analyst Reiterates Buy on Aktis Oncology, Maintains $34 Price Target Following Encouraging AKY-2519 ASCO Update

Alec Stranahan, an analyst from Bank of America Securities, maintained the Buy rating on Aktis Oncology, Inc.. The...

5M ago

AKTS

Aktis Oncology Initiated at Buy on Promising AKY-2519 Safety Profile and Broad B7‑H3 Radiopharma Market Opportunity

William Blair analyst Alexandra Ramsey has reiterated their bullish stance on AKTS stock, giving a Buy rating on...

5M ago

AKTS

AKTS FAQ

What was Aktis Oncology, Inc.’s price range in the past 12 months?

Aktis Oncology, Inc. lowest stock price was $14.72 and its highest was $34.19 in the past 12 months.

What is Aktis Oncology, Inc.’s market cap?

Aktis Oncology, Inc.’s market cap is $890.47M.

When is Aktis Oncology, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Aktis Oncology, Inc.’s earnings last quarter?

Currently, no data Available

Is Aktis Oncology, Inc. overvalued?

According to Wall Street analysts Aktis Oncology, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aktis Oncology, Inc. pay dividends?

Aktis Oncology, Inc. does not currently pay dividends.

What is Aktis Oncology, Inc.’s EPS estimate?

Aktis Oncology, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aktis Oncology, Inc. have?

Aktis Oncology, Inc. has 53,746,670 shares outstanding.

What happened to Aktis Oncology, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Aktis Oncology, Inc.?

Currently, no hedge funds are holding shares in AKTS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Aktis Oncology, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-41.07%

Trailing 12-Months

Asset Growth

―

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Aktis Oncology, Inc.

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.

Aktis Oncology, Inc. (AKTS) Earnings & Revenues

Historic Earnings Reports

AKTS Stock 12 Month Forecast

Average Price Target

$35.80

▲(32.99% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","41":"$41","22.25":"$22.3","28.5":"$28.5","34.75":"$34.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,22.25,28.5,34.75,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.52,20.17230769230769,21.824615384615385,23.476923076923075,25.12923076923077,26.78153846153846,28.433846153846154,30.086153846153845,31.738461538461536,33.39076923076923,35.043076923076924,36.69538461538461,38.347692307692306,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.52,19.84923076923077,21.178461538461537,22.507692307692306,23.836923076923075,25.166153846153843,26.495384615384616,27.824615384615385,29.153846153846153,30.483076923076922,31.81230769230769,33.14153846153846,34.47076923076923,{"y":35.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.52,19.633846153846154,20.747692307692308,21.861538461538462,22.975384615384616,24.08923076923077,25.20307692307692,26.316923076923075,27.43076923076923,28.544615384615383,29.658461538461538,30.77230769230769,31.886153846153846,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.4,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.4,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.4,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.4,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.07,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.42,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.48,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.07,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.99,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.52,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >